Desselberger U, Pressler K, Erdmann G
Zentralbl Bakteriol Orig A. 1975 Jul;232(2-3):160-77.
The antihemagglutinin (AH) and antineuraminidase (AN) antibody response in 35 humans to a single vaccination with the aluminum oxide adsorbed influenza virus vaccine "Alorbat" was investigated. The vaccine contained the strains A/Hong Kong/1/68 (H3N2), A/Hong Kong/107/71 (H3N2), A/England/42/72 (H3N2) and B/Iowa/1/69. the rates of significant AH antibody titer increase ranged from 51 percent (against A/Hong Kong/68), 69 (against A/Hong Kong/71), 63 (against A/England/72) to 83 percent (against B/Iowa/69). Persons with high prevaccination titers failed to yield postvaccination antibody titer increase (table 1). Antibody titer increase measured against the neuraminidase of A/England/72 virus was recorded in 60 percent and against the neuraminidase of B/Iowa/69 virus in 31 percent (table 2). Using the neuraminidase of the recombinant strain (A/Bel/42 (H0)-A/Sing/57 (NS) as test antigen a significant titer increase in 32 percent of sera tested was found (table 2). The AN antibody titers against A/England/72 exceeded the titers against the A/Bel-A/Sing recombinant 3,67-5,42 fold. This finding was shown to be caused by additional reaction of anti-H3 antibody with A/England/72 virus resulting in steric hindrance of neuraminidase activity.
对35名受试者接种氧化铝吸附流感病毒疫苗“Alorbat”后的抗血凝素（AH）和抗神经氨酸酶（AN）抗体反应进行了研究。该疫苗包含A/香港/1/68（H3N2）、A/香港/107/71（H3N2）、A/英格兰/42/72（H3N2）和B/爱荷华/1/69毒株。AH抗体滴度显著升高的比例从51%（针对A/香港/68）、69%（针对A/香港/71）、63%（针对A/英格兰/72）到83%（针对B/爱荷华/69）不等。接种前滴度较高的人接种后抗体滴度未升高（表1）。针对A/英格兰/72病毒神经氨酸酶的抗体滴度升高记录为60%，针对B/爱荷华/69病毒神经氨酸酶的为31%（表2）。以重组毒株（A/比利时/42（H0）-A/新加坡/57（NS））的神经氨酸酶作为检测抗原，发现32%检测血清的滴度显著升高（表2）。针对A/英格兰/72的AN抗体滴度超过针对A/比利时-A/新加坡重组体的滴度3.67至5.42倍。这一发现表明是抗H3抗体与A/英格兰/72病毒的额外反应导致神经氨酸酶活性的空间位阻所致。
